The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

In updated 2025 American Society of Hematology guidelines, recommendations are presented for the management of newly ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical ...

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

Review of current and emerging treatments for older adults with acute myeloid leukemia, highlighting venetoclax plus hypomethylating agents and future targeted therapy combinations in routine care.

TIBSOVO is a targeted therapy that works against an abnormal protein created by a mutation in the IDH1 gene. This abnormal protein plays an important role in the development of AML because it prevents ...

Acute myeloid leukemia (AML) is a rare, fast-growing cancer that starts in the bone marrow. The disease promotes the ...

An expert panel now recommends using certain personalized therapies in the frontline setting for older adults with FLT3- and IDH1-mutant disease.